
Sun Pharma’s New Jersey manufacturing overhaul puts 96 jobs at risk
pharmafile | November 26, 2018 | News story | Manufacturing and Production, Sales and Marketing | Sun Pharma, manufacturing, pharma
Indian pharma firm Sun Pharma has announced it is to combine its New Jersey manufacturing operations in a bid to “improve cost efficiencies, it has emerged – a move which puts almost 100 jobs at risk.
Specifically, the company plans to relocate operations at its facility in Cranbury to its site in New Brunswick, which will threaten 96 positions. The firm’s intention was confirmed in a WARN notice published by the New Jersey Department of Labor and Workforce Development
“Sun Pharma is consolidating its manufacturing operations at New Brunswick and Cranbury into one location, New Brunswick,” a company spokesperson said. “The restructuring is aimed at optimising our manufacturing operations and improving cost efficiencies in the increasingly competitive US market.”
The company confirmed that the affected employees will receive a severance package and will able to relocate.
“We are offering full support to the employees at Cranbury and helping them with internal reallocations and outplacement services.”
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

CARBOGEN AMCIS manufacturing license advances services in China
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …

Meribel Pharma Solutions launches to take pharma services to new heights
Meribel Pharma Solutions, a new mid-sized contract development and manufacturing organisation (CDMO), has officially launched …






